Case report of primary membranous nephropathy associated with muscle and peripheral nerve damage
https://doi.org/10.36485/1561-6274-2022-26-3-95-101
Abstract
Primary membranous nephropathy (PMN) typical cause of nephrotic syndrome in adults. The key point in its pathogenesis is the production of IgG4 subclass autoantibodies (IgG4) against podocytic transmembrane phospholipase A2 M-type receptor (anti-PLA2R), followed by the deposition of subepithelial immune complexes (IC) in situ. We present a case of a 37-year-old young man with PMN associated with demyelinating polyneuropathy and idiopathic inflammatory lesions of skeletal muscles demonstrating a possible variant of extrarenal effects of IgG4-anti-PLA2R with an extended analysis of diagnostics and probable mechanisms of imbalance of secreted and intracellular phospholipases.
About the Authors
Z. Sh. Kochoyan
Pavlov University
Russian Federation
Russian Federation
Zinaida Sh. Kochoyan, clinical resident
Department of Propedeutics of Internal Diseases with the Clinic
197022
L. Tolstoy st., 17, build. 54
Saint Petersburg
Phone: +7(812)338-69-22
O. B. Bystrova
Pavlov University
Russian Federation
Russian Federation
Olga B. Bystrova, nephrologist
Research Institute of Nephrology
2nd Nephrology Unit
197022
L. Tolstoy st., 17, build. 54
Saint Petersburg
Phone: +7(812)338-69-22
V. A. Dobronravov
Pavlov University
Russian Federation
Russian Federation
Vladimir A. Dobronravov, Prof., MD, PhD, DSc, , Director, professor of the department
Department of Propedeutics of Internal Diseases with the Clinic
Research Institute of Nephrology
197022
L. Tolstoy st., 17, build. 54
Saint Petersburg
Phone: +7(812)338-69-01
References
1. Glassock R. J. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis 2010; 56 (1): 157–167. doi: 10.1053/j.ajkd.2010.01.008.
2. Beck L. H. Jr., Bonegio R. G., Lambeau G. et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361 (1): 11–21 doi:10.1056/NEJMoa0810457
3. Schlumberger W., Hornig N., Lange S. et al. Differential diagnosis of membranous nephropathy with autoantibodies to phospholipase A2 receptor 1. Autoimmun Rev 2014; 13 (2): 108–113. doi:10.1038/srep08803
4. Ma H., Sandor D. G., Beck L. H. Jr. The role of complement in membranous nephropathy. Seminars in Nephrology 2013; 33 (6): 531–542. doi:10.1016/j.semnephrol.2013.08.004
5. Yang Y., Wang Ch. Liping J. et al. IgG4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: an inspiration from a cross-sectional study. Immunol Res 2016; 64 (4): 919–930. doi: 10.1007/s12026-016-8790-1
6. Passerini P., Ponticelli C. Membranous nephropathy. In: Ponticelli C., Glassock R. (eds). Treatment of Primary Glomerulonephritis, 2nd ed. Oxford University Press: Oxford, UK, 2009:261–312. doi:10.1093/med/9780199552887.001.0001
7. Добронравов В. А. Новый подход к быстрой индукции ремиссии у больных при мембранозной нефропатии / В. А. Добронравов [и др.] // Терапевтический архив. – 2021. – 93 (6): 706–712. doi: 10.26442/00403660.2021.06.200865 / Dobronravov V. A., Bystrova O. B., Kochoyan Z. Sh., Fomicheva E. N. A novel approach to rapid induction of remission in primary membranous nephropathy. Ter arkh 2021; 93 (6): 706-712. (In Russ) doi:10.26442/00403660.2021.06.200865
8. Omerhoca S., Akkas S. A., Icen N. K. Multiple sclerosis: diagnosis and differential diagnosis. Noro Psikiyatr Ars 2018; 55 (1): 1–9. doi: 10.29399/npa.23418
9. Van den Bergh P. Y., Hadden R. D., Bouche P. et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. Eur J Neurol 2010; 17 (1): 356–363. doi:10.1111/j.1468-1331.2009.02930.x
10. Bohan A., Peter J. B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292 (7): 344–347. doi: 10.1056/NEJM197502132920706
11. Bohan A., Peter J. B. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292 (8): 403–407. doi: 10.1056/NEJM197502202920807
12. Kohli A., Tandon P., Kher V. Chronic inflammatory demyelinating polyradiculoneuropathy with membranous glomerulonephritis: report of one case. Clin Neurol Neurosurg 1992; 94 (1): 31–33. doi: 10.1016/0303-8467(92)90115-j
13. Mobbs R. J., Tuck R. R., Hurley B. Chronic inflammatory demyelinating polyneuropathy associated with membranous glomerulonephritis: case report. J Clin Neurosci 2000; 7 (5): 454–455. doi: 10.1054/jocn.1999.0235
14. Wong A. H. Y., Kokubun N., Fukami Y. et al. Chronic inflammatory demyelinating polyneuropathy with membranous nephropathy. J Peripher Nerv Syst 2015; 20 (1): 63–66. doi: 10.1111/jns.12113
15. Режим доступа: https://www.genecards.org/cgi-bin/carddisp.pl? gene=PLA2R1 [Available at: https://www.genecards.org/cgi-bin/carddisp.pl?gene=PLA2R1]
16. Режим доступа: https://www.ncbi.nlm.nih.gov/gene/22925 [Available at: https://www.ncbi.nlm.nih.gov/gene/22925]
17. Hanasaki K., Arita H. Phospholipase A2 receptor: a regulator of biological functions of secretory phospholipase A2. Prostaglandins Other Lipid Mediat 2002; 68–69: 71–82. doi: 10.1016/s0090-6980(02)00022-9
18. Liu W., Gao Ch., Dai H. et al. Immunological pathogenesis of membranous nephropathy: focus on PLA2R1 and its role. Front Immunol 2019; 10: 1809. doi:10.3389/fimmu.2019.01809
19. Dennis E. A., Cao J., Hsu Y. H. et al. Phospholipase A2 Enzymes: Physical structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention. Chem Rev 2011; 111 (10): 6130–6185. doi:10.1021/cr200085w
20. Quach N. D., Arnold R. D., Cummings B. S. Secretory Phospholipase A2 enzymes as pharmacological targets for treatment of disease. Biochem Pharmacol 2014; 90 (4): 338–348. doi:10.1016/j.bcp.2014.05.022
21. Sribar J., Krizaj I. Secreted phospholipids a2 – not just enzymes. Acta Chem Slovn 2011; 58 (4): 678–688. PMID: 24061115
22. Murakami M. Lypoquality control by Phospholipase A2 enzymes. Proc Jpn Acad Ser B Phys Biol Sci 2017; 93 (9): 677–702. doi: 10.2183/pjab.93.043
23. Galluzzi L., Kepp O., Krautwald S. et al. Molecular mechanisms of regulated necrosis. Semin Cell Dev Biol 2014; 35: 24–32. doi:10.1016/j.semcdb.2014.02.006
24. Augert A., Payre C., Launoit Y. et al. The M-type Receptor PLA2R Regulates Senescence Through the p53 Pathway. EMBO Rep 2009; 10 (3): 271–277. doi:10.1038/embor.2008.255
25. Pan Y., Wan J., Liu Y. et al. sPLA2 IB induces human podocyte apoptosis via the M-type Phospholipase A2 receptor. Sci Rep 2014; 4: 6660:1–11. doi:10.1038/srep06660
26. Yagami T., Ueda K., Asakura K. et al. Group IB secretory Phospholipase A2 induces neuronal cell death via apoptosis. J Neurochem 2002; 81 (3): 449–461. doi:10.1046/j.1471-4159.2002.00800.x
27. Tappia P., Singal T., Dent M. et al. Phospholipid-mediated signaling in diseased myocardium. Future Lipidol 2006; 1 (6): 701–717. doi:10.2217/17460875.1.6.701
28. Huijbers M. G., Querol L. A., Niks E. H. et al. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J Neurol 2015; 22 (8): 1151–1161. doi:10.1111/ene.12758
29. Querol L., Devaux J., Rojas-Garcia R. et al. Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nat Rev Neurol 2017; 13 (9): 533–547. doi: 10.1038/nrneurol.2017.84
30. Koneczny I. A new classification system for IgG4 Autoantibodies. Front Immunol 2018; 9: 97. doi: 10.3389/fimmu.2018.00097
31. Umehara H., Nakajima A., Nakamura T. et al. IgG4-related disease and its pathogenesis-cross-talk between innate and acquired immunity. Int Immunol 2014; 26 (11): 585–595. doi: 10.1093/intimm/dxu074
32. Ronco P., Debiec H. Anti-phospholipase A2 receptor antibodies and the pathogenesis of membranous nephropathy. Nephron Clin Pract 2014; 128 (3–4): 232–237. doi: 10.1159/000368588
Review
For citations:
Kochoyan Z.Sh., Bystrova O.B., Dobronravov V.A. Case report of primary membranous nephropathy associated with muscle and peripheral nerve damage. Nephrology (Saint-Petersburg). 2022;26(3):95-101. (In Russ.) https://doi.org/10.36485/1561-6274-2022-26-3-95-101
Views:
640
Email this article 